YOLFTbeta
GRAIL, LLC

GRAIL, LLC

GRAL · NASDAQ · Healthcare / Diagnostics & Research

115.89USD-5.46 (-4.50%)

Price History

Full chart

Market Stats

Previous Close121.35
Open121.95
Day Range114.00 – 122.00
52-Week Range41.50 – 166.48
Volume361.13K
Market Cap5.46B
P/E (TTM)0.00
Forward P/E1.21
EPS-9.22
Dividend Yield0.00%
Beta2.87
50-Day Avg119.91
200-Day Avg79.08

About

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Joshua J. Ofman M.D., M.S.H.S
  • Employees910
  • Headquarters250 S. Mathilda Avenue, Sunnyvale, CA, United States, 94086, USA
  • Websitehttps://grail.com

Leadership

  • Dr. Joshua J. Ofman M.D., M.S.H.SCEO & Director · b. 1965
  • Mr. Aaron FreidinCFO & Head of Corporate Development · b. 1979
  • Mr. Robert P. RagusaAdvisor · b. 1960
  • Mr. Paul CiccolellaSenior Vice President of Global Development & Operations
  • Dr. Satnam Alag Ph.D.Chief Technology Officer
  • Sir Harpal S. Kumar M.A., M.B.A., MEngChief Scientific Officer and President of Global Clinical & Medical Affairs
  • Mr. Abram Barth J.D., M.P.H.Chief Legal Officer & Corporate Secretary
  • Ms. Trish RowlandSenior Vice President of Corporate Communications
  • Ms. Alison HighlanderChief People Officer
  • Mr. Andrew John PartridgeChief Growth Officer · b. 1969

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0-14.61M55.55M93.11M125.59M147.17M
Growth (%)----+280.17%+67.61%+34.90%+17.18%
Cost of Revenue14.08M10.31M-114.61M172.00M188.72M203.62M209.75M
Gross Profit-14.08M-10.31M--100.00M-116.45M-95.61M-78.02M-62.57M
Gross Margin----684.39%-209.63%-102.69%-62.12%-42.52%
Operating Expense273.42M245.36M-1.17B5.33B1.42B2.11B471.59M
Operating Income-287.50M-255.66M-316.42M-1.27B-5.44B-1.52B-2.19B-534.16M
Operating Margin----8659.61%-9798.18%-1627.61%-1743.03%-362.95%
EBITDA-269.42M-243.14M-308.73M-1.21B-587.70M-638.22M-610.17M-378.16M
EBITDA Margin----8258.99%-1057.96%-685.48%-485.82%-256.95%
Net Income-275.72M-244.85M-312.16M-1.25B-5.40B-1.47B-2.03B-408.35M
Net Income Margin----8539.39%-9719.35%-1574.23%-1613.92%-277.47%
R&D223.16M167.09M192.91M460.21M329.58M338.75M322.38M195.79M
R&D as % of Total Revenue---3149.55%593.30%363.83%256.68%133.04%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets686.85M635.52M706.30M9.74B5.60B4.56B2.98B2.92B
Total Liabilities86.47M84.99M144.46M307.40M955.94M910.74M479.90M344.15M
Total Equity600.37M550.53M561.84M9.43B4.65B3.65B2.50B2.58B
Cash95.09M143.19M170.19M221.16M241.60M97.29M214.23M249.73M
Total Debt2.52M42.04M62.99M110.56M96.01M84.41M68.14M98.01M
Net Debt-92.57M-101.15M-107.21M-110.60M-145.59M-12.88M-146.09M-151.72M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-209.26M-245.79M-232.00M-688.13M-561.31M-595.80M-577.16M-299.01M
Investing Cash Flow-93.39M133.04M-12.79M344.81M-22.86M-12.89M-551.01M-85.05M
Financing Cash Flow300.62M160.33M275.11M394.74M604.82M463.77M1.24B423.32M
Capital Expenditure15.99M3.33M11.90M69.93M22.86M12.89M5.21M909.00K
Free Cash Flow-225.25M-249.13M-243.91M-758.06M-584.17M-608.69M-582.36M-299.92M
FCF to OCF107.64%101.36%105.13%110.16%104.07%102.16%100.90%100.30%

Earnings

Report DateAug 13, 2024Nov 12, 2024Feb 20, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Feb 19, 2026May 5, 2026Aug 5, 2026Nov 4, 2026Nov 11, 2026
EPS Estimate--6.43-4.97-3.80-3.56-3.26-2.53-1.96-2.91-2.78-2.84
EPS Actual-51.06-3.50-2.89-3.10-3.18-2.46-2.44-1.37-2.56-2.21-
Surprise-45.57%41.85%18.42%10.67%24.54%3.56%30.10%12.03%20.50%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap5.46B
Enterprise Value4.95B
Trailing P/E0.00
Forward P/E1.21
Price / Sales32.75
Price / Book2.30
EPS-9.22
Book Value54.82
Revenue (TTM)166.60M
Gross Profit (TTM)77.77M
EBITDA-398.32M
Profit Margin-243.80%
Operating Margin-332.04%
Return on Equity-17.31%
Return on Assets-12.97%
Shares Outstanding44.96M
Shares Float34.64M
Beta2.87
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 10 analystsTarget 139.44
  • Strong Buy
    5
  • Hold
    5

Ownership Breakdown

Institutions
86.38%
Insiders
4.76%
Retail / Other
8.86%

Top Institutional Holders

  • Farallon Capital Management, L.L.C.
    4.16M9.30%
  • Baker Bros Advisors LP
    4.03M9.00%
  • BlackRock Inc
    3.58M7.99%
  • Fort Hoosac Management, LLC
    3.10M6.93%
  • State Street Corp
    2.39M5.33%
  • PRIMECAP Management Company
    2.18M4.87%
  • Sessa Capital, L.P
    2.04M4.55%
  • Deep Track Capital, LP
    1.83M4.10%
  • Vanguard Capital Management, LLC
    1.64M3.67%
  • Morgan Stanley - Brokerage Accounts
    1.46M3.27%
  • Geode Capital Management, LLC
    991.38K2.22%
  • Dimensional Fund Advisors, Inc.
    749.34K1.67%
  • The Goldman Sachs Group Inc
    748.01K1.67%
  • Jefferies Financial Group Inc
    724.00K1.62%
  • Bank of America Corp
    723.44K1.62%
  • Casdin Capital, LLC
    480.00K1.07%

Top Fund Holders

  • PRIMECAP Odyssey Aggressive Growth
    1.58M3.53%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.30M2.91%
  • State Street® SPDR® S&P® Biotech ETF
    1.05M2.35%
  • iShares Russell 2000 ETF
    1.05M2.34%